ONCOLYTICS BIOTECH INC 8-K

What Happened On June 16, 2026, Oncolytics Biotech Inc. announced by press release (filed on Form 8-K) that it has obtained a new patent related to the manufacturing of pelareorep and provided additional updates to pelareorep’s intellectual property portfolio. The company disclosed the item under Item 8.01 (Other Events) of the Form 8-K; the press release was included as Exhibit 99.1. The filing was signed by Kirk Look, Chief Financial Officer, on June 16, 2026.

Key Details

• Form 8-K filed and dated June 16, 2026 (Item 8.01: Other Events).
• Company issued a press release on June 16, 2026 announcing a new patent concerning pelareorep manufacturing; the release is attached as Exhibit 99.1.
• Additional updates to the pelareorep intellectual property portfolio were announced (no patent numbers or further technical details were included in the 8-K).
• The Form 8-K was signed by Kirk Look, CFO, on June 16, 2026.

Why It Matters Intellectual property developments—like a new manufacturing patent and portfolio updates—are directly relevant to the company’s ability to protect and commercialize pelareorep. For investors, stronger IP coverage can affect manufacturing control, potential licensing opportunities, and the overall value of the asset; the company’s public disclosure signals ongoing work to secure those rights. Investors should watch for future filings or press releases that provide patent numbers, scope, grant jurisdiction, or any related licensing or commercialization plans.